CCR2 and Patent ductus arteriosus: Given collective findings by us and others showing a predominant immunosuppressive TAM phenotype in PDA and our data from KPC-CCR2–/– mice, we sought to deplete bone marrow–derived monocytes to test the hypothesis that depletion of infiltrated TAMs is an avenue for the development of new combination immunotherapies for PDA.